Pacira BioSciences
(NASDAQ) PCRX
Pacira BioSciences Financials at a Glance
Market Cap
$942.47M
Revenue (TTM)
$734.86M
Net Income (TTM)
$5.14M
EPS (TTM)
$0.12
P/E Ratio
191.83
Dividend
$0.00
Beta (Volatility)
0.58 (Low)
Dividend
$0.00
Beta (Volatility)
0.58 (Low)
Price
$24.10
Volume
167,394.319
Open
$23.93
Price
$24.10
Volume
167,394.319
Open
$23.93
Previous Close
$23.96
Daily Range
$23.85 - $24.49
52-Week Range
$18.80 - $27.64
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
0.58 (Low)
Price
$24.10
Volume
167,394.319
Open
$23.93
Previous Close
$23.96
Daily Range
$23.85 - $24.49
52-Week Range
$18.80 - $27.64
Estimated Earnings Date
Aug 4, 2026
PCRX News
PCRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Pacira BioSciences
Industry
Pharmaceuticals
Sector
Health CareEmployees
829
CEO
Frank D. Lee, MBA
Website
www.pacira.comHeadquarters
Tampa, FL 33609, US
PCRX Financials
Key Financial Metrics (TTM)
Gross Margin
79.34%
Operating Margin
3.09%
Net Income Margin
0.70%
Return on Equity
0.73%
Return on Capital
2.90%
Return on Assets
0.43%
Earnings Yield
0.52%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$942.47M
Shares Outstanding
39.34M
Volume
167.39K
Avg. Volume
525.08K
Financials (TTM)
Gross Profit
$583.01M
Operating Income
$22.68M
EBITDA
$118.40M
Operating Cash Flow
$142.22M
Capital Expenditure
-$9.51M
Free Cash Flow
$132.71M
Cash & ST Invst.
$202.18M
Total Debt
$411.18M
Pacira BioSciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$177.38M
+5.0%
Gross Profit
$140.96M
+4.7%
Gross Margin
79.47%
N/A
Market Cap
$942.47M
N/A
Market Cap/Employee
$1.20M
N/A
Employees
788
N/A
Net Income
$2.92M
-39.4%
EBITDA
$29.51M
-12.2%
Quarterly Fundamentals
Total Cash
$202.18M
-59.0%
Total Debt
$411.18M
-35.4%
Accounts Receivable
$125.64M
+19.9%
Inventory
$150.37M
+12.4%
Long Term Debt
$401.36M
-5.6%
Short Term Debt
$9.82M
-95.4%
Return on Assets
0.43%
N/A
Return on Invested Capital
2.06%
N/A
Free Cash Flow
$22.96M
-14.7%
Operating Cash Flow
$25.68M
-27.6%